BsUFA Revenue Missed Estimates Again In FY2019
Spending Reduced To Account For Shortfall
Executive Summary
US FDA said that total BsUFA obligations also decreased compared to estimates, but maintains optimism about future revenue increases.
Topics
- Subjects
- Biosimilars
- User Fees
- FDA
- Regulation
- Review Pathway
- Regions
- North America
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GB150014
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
GB150014
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.